Literature DB >> 1847355

SCID mouse model of Epstein-Barr virus-induced lymphomagenesis of immunodeficient humans.

D T Purtilo1, K Falk, S J Pirruccello, H Nakamine, K Kleveland, J R Davis, M Okano, Y Taguchi, W G Sanger, K W Beisel.   

Abstract

Immunodeficient humans are at very high risk of developing Epstein-Barr virus (EBV)-induced lymphomagenesis. Severe combined immunodeficient mice (SCID) have been shown to develop lymphoproliferative disease (LPD) following transfer of peripheral blood leukocytes (PBL) with latent EBV. To study mechanisms of lymphomagenesis, we compared results of engraftment of PBL from normal donors and immunodeficient donors with X-linked lymphoproliferative disease (XLP). Graft-versus-host disease (GVHD) developed in 6 of 10 SCID mice 4 to 8 weeks following transfer of PBL from normal donors. In contrast, none of 9 mice engrafted with PBL from XLP patients with T-cell defects showed GVHD. LPD developed in mice regardless of the immune competence of the donors. The expression of EBV-encoded proteins, results of immunophenotyping, and karyotyping of the LPD lesions revealed lethal oligoclonal LPD owing to transfer of latent EBV in B cells in mice engrafted with PBL from seropositive donors. Polyclonal LDP developed in mice engrafted with PBL from seronegative patients which were infected with B95-8 virus 6 weeks after transfer of the cells. This model is useful for investigating mechanisms of EBV-induced LDP in immunodeficient patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847355     DOI: 10.1002/ijc.2910470407

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

1.  CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  S Nikiforow; K Bottomly; G Miller
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

Review 2.  SCID mice in the study of human autoimmune diseases.

Authors:  M A Duchosal
Journal:  Springer Semin Immunopathol       Date:  1992

Review 3.  Current status review: the severe combined immunodeficient (SCID) mouse: xenogeneic-SCID chimeras in the investigation of human autoimmune disease.

Authors:  P C Taylor
Journal:  Int J Exp Pathol       Date:  1992-04       Impact factor: 1.925

4.  Epstein-Barr viral genome in lymph nodes from patients with Hodgkin's disease may not be specific to Reed-Sternberg cells.

Authors:  A Masih; D Weisenburger; M Duggan; J Armitage; R Bashir; D Mitchell; R Wickert; D T Purtilo
Journal:  Am J Pathol       Date:  1991-07       Impact factor: 4.307

Review 5.  X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology.

Authors:  D T Purtilo
Journal:  Springer Semin Immunopathol       Date:  1991

6.  Hemagglutination and graft-versus-host disease in the severe combined immunodeficiency mouse lymphoproliferative disease model.

Authors:  S J Pirruccello; H Nakamine; K W Beisel; K L Kleveland; M Okano; Y Taguchi; J R Davis; M L Mahloch; D T Purtilo
Journal:  Am J Pathol       Date:  1992-05       Impact factor: 4.307

Review 7.  Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders.

Authors:  M A Nalesnik; T E Starzl
Journal:  Transplant Sci       Date:  1994-09

8.  Characterization of hu-PBL-SCID mice with high human immunoglobulin serum levels and graft-versus-host disease.

Authors:  M A Duchosal; S A Eming; P J McConahey; F J Dixon
Journal:  Am J Pathol       Date:  1992-11       Impact factor: 4.307

9.  SCID-Hu mice immunized with a pneumococcal vaccine produce specific human antibodies and show increased resistance to infection.

Authors:  I S Aaberge; T E Michaelsen; A K Rolstad; E C Groeng; P Solberg; M Løvik
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

10.  Characterization of clonality of Epstein-Barr virus-induced human B lymphoproliferative disease in mice with severe combined immunodeficiency.

Authors:  H Nakamine; A S Masih; M Okano; Y Taguchi; S J Pirruccello; J R Davis; M L Mahloch; K W Beisel; K Kleveland; W G Sanger
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.